2211.HK Universal Health Intl (HKSE) +129.93% Jan 2026: volume spike, valuation
The 2211.HK stock surged intraday to HK$3.15, up 129.93%, on a heavy trade of 4,118,440 shares as of this session in Hong Kong (HKSE). This move followed an open at HK$1.39 and a session high of HK$3.20, with average volume normally near 76,335 shares. The spike makes 2211.HK one of today’s high volume movers in the Healthcare sector and forces a re-check of valuation, liquidity and near-term catalysts.
2211.HK stock intraday move and volume
The intraday rally shows strong buying interest: price moved from HK$1.39 to a high of HK$3.20 today on volume of 4,118,440, roughly 54.0 times average volume. The unusually high relative volume indicates either news-driven flows or active trading interest from retail and momentum desks. Traders should treat the jump as high-volatility action rather than a confirmed trend until follow-through appears on lower volume.
Price action, support and resistance levels
Key intraday levels: day low HK$1.39, day high HK$3.20, and previous close HK$1.37. Short-term support sits near the session pivot at HK$1.75 (50-day average HK$1.77) and next structural support around HK$1.40. Resistance on a sustained move would be tested near the company book-value implied level of HK$3.96.
Fundamentals and valuation vs Healthcare sector
Universal Health International Group Holding Limited (2211.HK, HKSE) reports EPS -0.36 and PE -3.58, reflecting trailing losses. Book value per share is HK$3.96, giving a price-to-book of 0.29, well below the Healthcare sector average PB near 2.51. The company’s price-to-sales ratio is 0.13, and currentRatio is 1.31, which highlights low market pricing versus asset backing but also continued margin pressure.
Technical indicators and trading signals
Technicals show heavy short-term momentum shifts: RSI at 17.59 (oversold turned rapid rebound) and MACD histogram recently negative. Bollinger band middle is HK$1.75 with upper HK$2.07 and lower HK$1.44; today’s spike pierced the upper band. Traders should note ATR HK$0.04 and on-balance volume deeply negative historically, now reversing intraday. These signals imply a volatile mean-reversion setup rather than steady trend.
Meyka grade and analyst view
Meyka AI rates 2211.HK with a score out of 100: 60.02 (B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The proprietary grade balances the cheap valuation metrics against negative profitability and weak interest coverage. Market commentary from analysts remains sparse; no price-target consensus is published publicly.
Risks, catalysts and trading considerations
Key near-term catalysts include company announcements, earnings updates, or material corporate actions that could explain the volume surge. Risks include persistent net losses, negative margins (net margin -3.66%), and a limited analyst coverage profile which increases event risk. For intraday traders, set tight stops and use scaled exposure given the skewed risk-reward after a large one-day move.
Final Thoughts
Key takeaways for the intraday high-volume move: 2211.HK stock traded HK$3.15 today, a +129.93% change on 4,118,440 shares, far above its average. Valuation metrics show a low price-to-book of 0.29 versus the Healthcare peer PB near 2.51, suggesting the market prices in continued earnings weakness. Meyka AI’s forecast model projects a yearly target of HK$3.29, an implied upside of 4.33% from the current price HK$3.15. Traders should weigh the small model upside against the high intraday volatility and potential downside to session support near HK$1.40. Forecasts are model-based projections and not guarantees. For more details, see the company site and filings, and our real-time note on the Meyka AI stock page for 2211.HK
FAQs
What caused the intraday jump in 2211.HK stock?
Intraday jumps often follow a news event, speculative flows, or low-float trading. Today’s increase to HK$3.15 on volume of 4,118,440 suggests event-driven or momentum buying; check company announcements and HKEX disclosures for confirmation.
Is 2211.HK stock undervalued relative to peers?
At a price-to-book of 0.29 and book value per share HK$3.96, 2211.HK looks inexpensive versus the Healthcare PB average near 2.51. However negative EPS and weak margins justify caution before assuming re-rating.
What is Meyka AI’s short-term forecast for 2211.HK stock?
Meyka AI’s forecast model projects a yearly price near HK$3.29, implying about 4.33% upside from HK$3.15. Forecasts are model-based projections and not guarantees; traders should manage risk accordingly.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
